At the present time, the choice of the best molecular targeted agent and the appropriate combination therapy for a specific patient with cancer is largely empirical. Nevertheless, the rapid ...
This seminar is open to the research community. Thursday, November 9, 2023 - 11:00 a.m. to 12:00 p.m.
Treatment landscape of EGFR-mutant non–small cell lung cancer has evolved in the most recent years. In the metastatic setting, with combination approaches tested in first-line, whereas in the ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2008 ASCO Annual Meeting. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback